A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
argenx
Study ID
NCT06637072
Phase
PHASE4
Status
Completed

Conditions

  • Chronic Inflammatory Demyelinating Polyneuropathy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.

Key Dates

Start date
Dec 10, 2024
Status verified
Apr 2026
Primary completion
Feb 19, 2026
Completion
Feb 19, 2026

Study Design

Enrollment
23 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Efgartigimod PH20 SC
    Participants start efgartigimod PH20 SC treatment after discontinuing IVIg

Primary Outcome Measure

Proportion of participants who begin treatment with efgartigimod PH20 SC within 1 week after stopping IVIg therapy and are still receiving efgartigimod PH20 SC at the end of the 12-week treatment period [ Time Frame: Up to 12 weeks ]

Locations (13)

FacilityCityStateZIPSite coordinators
MedStar Washington Hospital CenterWashington D.C.District of Columbia20010-
Neurology Associates PAMaitlandFlorida32751-
Visionary Investigators NetworkMiamiFlorida33180-
Northwestern Memorial HospitalChicagoIllinois60611-
Velocity Clinical ResearchLafayetteLouisiana70508-
SRI International - ClinEdgePlymouthMichigan48170-
Velocity Clinical ResearchRaleighNorth Carolina27607-
Erlanger Neuroscience InstituteChattanoogaTennessee37403-
Vanderbilt University Medical CenterNashvilleTennessee37232-
National Neuromuscular Research InstituteAustinTexas78759-
Horizon Clinical Research: Gill NeuroscienceCypressTexas21216-
Northwest Houston Neurology - CypressCypressTexas77429-
Cedar Health Research - DallasDallasTexas75251-

Find similar trials in Washington D.C., DC

Related Studies